The T cell receptor (TCR) is an engineered receptor modality used in T cell engineering to reprogram effector cells and redirect them toward new antigen specificities. In this context, it functions as a recognition module that can be adapted for tumor targeting, rather than only native antigen sensing. Structural work shows ny eso 1 157–165 recognition by TCRs, highlighting peptide-specific binding at the core of its mechanism. This makes TCR platforms relevant to cancer immunotherapy, especially for antigen-directed cell therapies and strategies to overcome checkpoint resistance. Recent literature also frames in vivo site-specific engineering as a way to reprogram T cells, underscoring the translational push toward programmable receptor systems.
Cancer / Immunotherapy
- Engineered TCR platforms were described as a strategy to redirect effector cells toward novel tumor specificity, supporting their use in adoptive cell therapy design. (PMID:41661081)
- A 2026 Clinical Cancer Research paper (PMID:41661081) placed TCR-based approaches alongside bispecific engagers as strategies against checkpoint resistance.
- Structural analyses linked TCR recognition to the ny eso 1 157–165 peptide, a tumor-associated antigenic epitope relevant to immunotherapy. (PMID:41846058)
- A 2026 International Immunopharmacology review/meta-analysis (PMID:41846058) discussed NY-ESO-1 in triple-negative breast cancer and its immunotherapeutic implications, providing disease context for TCR targeting.
- In vivo site-specific engineering to reprogram T cells was highlighted in a 2026 Nature study, reinforcing TCR engineering as a practical reprogramming modality. (PMID:41851456)